Chronic hepatitis B – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Chronic hepatitis B infection is defined as HBsAg in the serum for six months. HBeAg and HBV DNA (measured using a polymerase chain reaction (PCR) assay) are viral replication and infectivity markers, whereas HBsAg is a hepatitis B viral infection marker. Cirrhosis, liver failure, hepatocellular carcinoma, and death are severe complications of chronic infection. HBV DNA can be found in the serum without HBeAg in a small percentage of patients. The "precore" mutant in these patients prevents completion and excretion of the "e" antigen despite active HBV DNA replication and is linked to progressive liver disease.

The risk of developing chronic hepatitis B after acute HBV infection is age-dependent; approximately 90% of infants become chronically infected. Less than 5% of adults experience chronic illness.

If HBV transmission occurs at age ≤5 years, long‐term consequences such as chronic hepatitis, cirrhosis, or HCC would be significant problems.

The competitive landscape of Chronic hepatitis B includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Chronic hepatitis B across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic hepatitis B Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Chronic hepatitis B – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          VIR-2218          Vir Biotechnology, Inc.   Phase 2

2          ABI-H2158        Assembly Biosciences   Phase 2

3          APG-1387         Ascentage Pharma Group Inc.   Phase 2

4          LDT600 (Telbivudine)    Novartis Pharmaceuticals          Phase 1

5          NCO-48 Fumarate         Nucorion Pharmaceuticals, Inc.  Phase 1

6          CKD-388 Tab.   Chong Kun Dang Pharmaceutical           Phase 1

7          ChAd155-hIi-HBV          GlaxoSmithKline            Phase 2

8          EYP001a          Enyo Pharma    Phase 1

9          Peginterferon alfa-2b injection    Xiamen Amoytop Biotech Co., Ltd.            Phase 3

10        IMC-I109V        Immunocore Holdings Plc          Phase 1

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more